Focused On-demand Library for Serine/threonine-protein kinase Kist

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Kinase interacting with stathmin; PAM COOH-terminal interactor protein 2; U2AF homology motif kinase 1

Alternative UPACC:

Q8TAS1; A0A0A6YYC2; A8K8K4; G3V1M1; Q96C22


Serine/threonine-protein kinase Kist, also known as Kinase interacting with stathmin, PAM COOH-terminal interactor protein 2, and U2AF homology motif kinase 1, plays a crucial role in cell cycle progression. Upon serum stimulation, it phosphorylates CDKN1B/p27Kip1, influencing CDKN1B's subcellular location and facilitating G1 phase progression. Its potential involvement in RNA trafficking and processing highlights its multifaceted biological functions.

Therapeutic significance:

Understanding the role of Serine/threonine-protein kinase Kist could open doors to potential therapeutic strategies. Its pivotal role in cell cycle regulation and RNA processing presents a unique opportunity for targeted drug discovery, aiming to modulate its activity for therapeutic benefits.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.